Autopsy report · NCT01287741

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

“The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 6 years 6 months before it stopped.
• 1,418 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

Rituximab; Obinutuzumab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone

Participants

1,418

Sites

235

Countries

Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Czechia, Denmark, Germany, Hong Kong, Hungary and more

Trials that died the same way

• Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
  “The study was put on clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.” (76% match in meaning)
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
  “Study closed due to slow accrual and lack of efficacy.” (75% match in meaning)
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
  “The lack of adequate funding has made it impossible to continue with the clinical study As this study was not initiated, no subject was included and no data was collected,thus no result can be obtained SPONSOR\_DECISION End of trial date:15 Oct 2025” (74% match in meaning)
• Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
  “This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.” (74% match in meaning)
• Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
  “The study was closed after \> 1 year of inactivity.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.